PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research

Core Viewpoint - PharmAla Biotech Holdings Inc. has entered into an agreement with Østfold Hospital Trust of Norway to supply LaNeo™ MDMA for research into its potential as a treatment for Major Depressive Disorder [1][2] Group 1: Agreement Details - The agreement includes financial and data-sharing provisions, with PharmAla aiming to ship LaNeo MDMA Clinical Research Materials to Østfold Hospital Trust as soon as regulatory approvals are obtained [2][3] - Østfold Hospital Trust selected PharmAla after a competitive review, citing the company's professionalism and understanding of regulatory and scientific requirements for clinical research [3] Group 2: Company Background - PharmAla is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for trials and commercial sales [5] - The company is the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates [5]